Alemtuzumab Efficacy and Safety Were Maintained over 8 Years in Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease from Care-Ms I: Topaz Study Follow-Up

AuthID
P-00R-46N
18
Author(s)
Achiron, A
·
Bass, AD
·
Bertolotto, A
·
Brandes, D
·
Chinea, A
·
Garcia, JR
·
Naismith, RT
·
Schippling, S
·
Sharrack, B
·
Sousa, L
·
Tintore, M
·
Traboulsee, A
·
Uitdehaag, BMJ
·
Ziemssen, T
·
Choudhry, Z
·
Daizadeh, N
·
Pelletier, D
Document Type
Abstract
Year published
2019
Published
in MULTIPLE SCLEROSIS JOURNAL, ISSN: 1352-4585
Volume: 25, Pages: 535-536 (2)
Conference
35Th Congress of the European-Committee-For-Treatment-And-Research-In-Multiple-Sclerosis (Ectrims) / 24Th Annual Conference of Rehabilitation in Ms, Date: SEP 11-13, 2019, Location: Stockholm, SWEDEN, Sponsors: European Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltd
Indexing
Publication Identifiers
Wos: WOS:000485303102192
Source Identifiers
ISSN: 1352-4585
Export Publication Metadata
Marked List
Info
At this moment we don't have any links to full text documens.